Patrick Soon-Shiong is a surgeon, scientist, inventor, and biotechnology entrepreneur. He is Founder and Chairman of NantWorks and ImmunityBio, and Executive Chairman of the Los Angeles Times. Dr. Soon-Shiong founded and led American Pharmaceutical Partners and Abraxis BioScience and is the inventor of nab-paclitaxel (Abraxane), a nanoparticle-based chemotherapy and a landmark advance in translational oncology. As a surgeon, he is one of the very first to perform encapsulated human islet cell transplant, pioneering cellular therapies for diabetes.
Through ImmunityBio he and his team have developed Anktiva, an interleukin-15 (IL-15) receptor agonist, that is already approved by the U.S. FDA with BCG for the treatment of adult patients with BCG unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors, and is currently being tested for multiple indications. He has initiated and is hosting video series called “Cancer Decoded” with Mark Halperin, aiming to change the way we talk about cancer, and make it easier to understand, through open and honest conversations with the 2WAY community.
Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and the Chan Soon-Shiong Institute of Molecular Medicine, supporting biomedical research and global health innovation. His contributions have been recognized with numerous honors, including the National Medal of Technology and Innovation, the Lasker–DeBakey Clinical Medical Research Award, and the Franklin Institute Award.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
